Phase 1 Head and Neck Cancer Trial, Recruiting NCT07040072 Sponsor: Beijing Tongren Hospital Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 1 Head and Neck Cancer Trial, Recruiting

NCT07040072
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to sign a consent form agreeing to take part
  • You have head and neck cancer (in the mouth, throat, or voice box area) that has come back or spread to other parts of the body
  • You are 18 years old or older and are generally able to carry out daily activities with little or no difficulty (confirm with trial site)
  • Your cancer got worse within 24 weeks of your last immunotherapy treatment (with or without platinum-based chemotherapy)
  • You have at least one measurable area of cancer that can be tracked during the trial
  • You may be asked to provide a tissue sample for a protein test (PD-L1), if one has been done before
  • You are expected to live for more than 3 months
  • Your blood, kidney, liver, and clotting test results meet certain minimum health levels within 7 days before joining (confirm with trial site for specific numbers)

Who may not be able to join:

  • Your cancer could be treated with a local procedure (such as surgery or radiation to one area)
  • You have another type of cancer at the same time
  • Your cancer has spread to the brain
  • You still have significant side effects from a previous treatment that have not cleared up (excluding long-term, ongoing side effects)
  • You have a known allergy to any ingredient in the trial medications
  • You have had major surgery, radiation therapy, chemotherapy, immunotherapy, or certain other cancer treatments within the 4 weeks before joining
  • You have received certain other cancer treatments (including targeted therapy or immune-boosting drugs) within the 2 weeks before joining
  • You have taken immune-suppressing medications within the 4 weeks before joining (certain short-term or low-dose exceptions may apply — confirm with trial site)
  • You have an active infection requiring antibiotics, active tuberculosis, active hepatitis C, significant hepatitis B levels in your blood, or HIV
  • You have fluid build-up around your lungs, abdomen, or heart that cannot be controlled
  • You have previously had a severe immune-related side effect from immunotherapy (serious inflammation of any organ, or heart inflammation of moderate severity or worse)
  • You have had a serious heart or blood vessel problem within the last 6 months (such as heart failure, heart attack, stroke, or blood clots), have certain abnormal heart test results, or have uncontrolled high blood pressure
  • You have an active autoimmune disease (a condition where your immune system attacks your own body)
  • You have a significant risk of serious bleeding
  • You have received a live vaccine within 4 weeks before joining
  • You are pregnant, breastfeeding, or able to have children but not using contraception
  • You have a mental health condition that could affect your ability to take part in the trial
  • You have had an organ transplant or stem cell transplant in the past

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Luo Zhang, Beijing Tong-Ren hospital

Phone: (86)13910830399

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Beijing Tongren Hospital
Registry
ClinicalTrials.gov
Start date
9 October 2025
Est. completion
1 June 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Adverse events (AEs); Overall response rate (ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov